PwPepwise

Thymosin Alpha-1

Immune Support

a.k.a. Zadaxin

Thymic peptide

Thymosin Alpha-1 (Tα1) is a naturally occurring peptide derived from the thymus gland that plays a central role in regulating the immune system.

§Dosing at a glance

5 protocols · from the research
What it's forDoseHow oftenHowFor how long
Chronic Hepatitis B1.6 mgWeeklySubcutaneousInjected just under the skin, into the fat layer.104 wks
Severe Sepsis1.6 mg—SubcutaneousInjected just under the skin, into the fat layer.—
Acute Necrotising Pancreatitis1.6 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.14 days
Metastatic Melanoma1.6 mg—SubcutaneousInjected just under the skin, into the fat layer.—
Allogeneic Hematopoietic Transplantation (registered trial)1.6 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.16 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Thymosin Alpha-1 (Tα1) is a naturally occurring peptide derived from the thymus gland that plays a central role in regulating the immune system. It works by activating and balancing key immune cells — particularly T lymphocytes — helping the body mount more effective responses to infections, cancer, and other immune challenges. In clinical research, Tα1 has been most extensively studied in the context of chronic viral hepatitis, sepsis, and cancer immunotherapy.

In patients with chronic hepatitis B, Tα1 monotherapy has been reported to achieve ALT normalization in roughly one-third of patients and HBeAg clearance in approximately one-quarter at 72-week follow-up3. In severe sepsis, Tα1 may reduce 28-day mortality and appears to restore measurable immune function by improving monocyte activity6. In metastatic melanoma, Tα1 combined with chemotherapy may extend response duration in a subset of patients2. For acute exacerbations of chronic obstructive pulmonary disease, pooled data suggest Tα1 may improve lung function, blood oxygen levels, and shorten hospital stays9. Its tolerability profile across these settings has been consistently favorable, with no serious drug-related adverse events reported in major trials2,3,5,6. Research into additional indications — including lung cancer, transplant immunology, and immune-related adverse events from checkpoint inhibitors — is actively underway16,20.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Thymosin Alpha-1 is a 28-amino acid acetylated peptide (molecular weight approximately 3,108 Da) originally isolated from thymosin fraction 5 of bovine thymus tissue. Its primary mechanism of action involves the modulation of innate and adaptive immune signaling, operating at the intersection of T lymphocyte maturation, dendritic cell activation, and cytokine network regulation.

At the cellular level, Tα1 engages Toll-like receptors (TLRs) — particularly TLR2 and TLR9 — on dendritic cells and macrophages, triggering downstream MyD88-dependent signaling cascades that promote the production of type I interferons and pro-inflammatory cytokines while simultaneously modulating regulatory pathways to prevent excessive immune activation. This dual modulatory capacity — simultaneously immunostimulatory in states of immunosuppression and potentially immunoregulatory in states of dysregulated inflammation — underlies its investigation across seemingly divergent clinical contexts, from infectious immunoparalysis to immune-related adverse events from checkpoint inhibitors16.

In T lymphocyte biology, Tα1 promotes the differentiation and functional maturation of CD4+ helper T cells and CD8+ cytotoxic T cells from immature precursors, and has been shown in clinical studies to increase CD4+ T cell percentages and normalize CD4+/CD8+ ratios in immunosuppressed patient populations8,9. Mechanistic data from the ETASS sepsis trial demonstrated that Tα1 significantly restored monocyte HLA-DR expression — a validated biomarker of innate immune competence — at days 3 and 7 of treatment, providing direct in-human evidence of its immunorestorative activity in a context of severe acquired immunosuppression6.

Tα1 also interacts with the endogenous cytokine axis by upregulating interleukin-2 receptor expression on lymphocytes and enhancing IL-2-driven lymphocyte proliferation, a mechanism that formed part of the rationale for its early investigation in combination with IL-2 in HIV immunodeficiency14. In the antiviral setting, its immunomodulatory activity is thought to reconstitute virus-specific T cell responses that become exhausted during chronic infection, producing the delayed but durable viral suppression and seroconversion patterns observed in hepatitis B trials3,11.

Pharmacokinetically, Tα1 is administered exclusively by the subcutaneous route due to its susceptibility to gastrointestinal degradation. Following subcutaneous injection, it is rapidly absorbed, with peak plasma concentrations typically achieved within one to two hours. The peptide is cleared through enzymatic degradation and renal filtration with a relatively short plasma half-life, necessitating the twice-weekly or more frequent dosing regimens observed across clinical trials2,3,5. No significant accumulation or dose-dependent pharmacokinetic nonlinearity has been described across the 0.8 mg to 6.4 mg dose range studied in human trials2,3.

§04Evidence & efficacy

Evidence base
290Studies
182Human
42Animal

Thymosin Alpha-1's efficacy evidence spans multiple indications, with the strength of evidence varying considerably across them.

In chronic hepatitis B, Tα1 monotherapy at 1.6 mg has been reported to achieve ALT normalization in 36.4% of patients and HBV-DNA clearance in approximately 30% at 72-week follow-up, with HBeAg clearance in 22.8%3. Patients with advanced fibrosis appear to derive greater benefit from the higher dose3. When compared head-to-head with interferon-alpha, Tα1 showed a delayed but more durable response pattern, with sustained response rates improving from 31% at end of treatment to 48.3% at six-month follow-up11. Combination with entecavir may accelerate early virological responses at 24 weeks compared to entecavir monotherapy, though these advantages appear to attenuate by 48–52 weeks10.

In severe sepsis, Tα1 may reduce 28-day all-cause mortality from approximately 35% to 26% and appears to restore monocyte HLA-DR expression, a marker of immune function, at days 3 and 7 of treatment6. A 2025 meta-analysis of five RCTs in severe acute pancreatitis suggests Tα1 increases CD4+ T cell percentages and CD4+/CD8+ ratios while reducing infectious complications8.

In acute exacerbations of COPD, pooled data suggest Tα1 may improve FEV1, arterial blood oxygen levels, and immune cell profiles, with a clinically meaningful reduction in hospital length of stay of approximately 5.4 days9.

In metastatic melanoma, Tα1 at 3.2 mg combined with dacarbazine may extend response duration in a subset of patients, with some responders maintaining responses up to 23.2 months compared to a maximum of 8.4 months in controls2.

In severe acute necrotising pancreatitis, a large well-powered double-blind RCT of 508 patients found no significant reduction in the incidence of infected pancreatic necrosis or other major complications compared to placebo1.

Registered trials in early-stage NSCLC post-resection12, locally advanced NSCLC after chemoradiotherapy20, and immune-related adverse events from checkpoint inhibitors16 are actively developing the evidence base.

§05Safety

Thymosin Alpha-1 has demonstrated a consistently favorable tolerability profile across the full breadth of its clinical research program. In well-powered double-blind RCTs, no serious drug-related adverse events were recorded1,6. In the hepatitis B setting, adverse drug reactions were mild and primarily consisted of transient fluctuations in liver enzyme levels, an effect attributed to positive immunomodulatory activity rather than direct toxicity, and occurred at comparable rates across both the 0.8 mg and 1.6 mg dose levels3. In the metastatic melanoma program, addition of Tα1 to dacarbazine and interferon-alpha at doses up to 6.4 mg did not introduce additional toxicity compared to chemotherapy controls2. In elderly patients aged 65–99 years receiving Tα1 as a vaccine adjuvant, no toxicity was observed in either the active or placebo groups5. A pooled meta-analysis of Tα1 combined with entecavir in HBV-related cirrhosis reported a significantly lower adverse event rate for the combination regimen compared to entecavir monotherapy (RR=0.48)10. No drug interactions or contraindications have been reported across published studies. Long-term safety data extending beyond 104 weeks are an area of active clinical investigation4.

§06History

Thymosin Alpha-1 was first isolated and characterized in the 1970s by Allan L. Goldstein and colleagues at George Washington University, emerging from systematic biochemical fractionation of thymic extracts intended to identify the active immunological components of the thymus gland. The discovery arose within the broader scientific context of elucidating thymus-dependent immune function — a field galvanized by the recognition that thymic involution contributes to age-related immunosenescence. Early research in the 1980s established Tα1's capacity to augment vaccine antibody responses in elderly populations5, setting the stage for its clinical development as an immune adjuvant.

Throughout the 1990s and early 2000s, Tα1 was developed commercially under the brand name Zadaxin (SciClone Pharmaceuticals) and received regulatory approval in numerous Asian and emerging market countries — most prominently China — for treatment of chronic hepatitis B and C, as well as use as a vaccine adjuvant. It was never approved by the FDA or EMA, though it has been the subject of multiple sponsored clinical programs in Western markets2,7.

Key development milestones include the Japanese chronic hepatitis B RCTs3, the multicenter melanoma program2, and the ETASS sepsis trial6 in the 2000s–2010s. The 2022 multicenter pancreatitis RCT1 represented the largest and most rigorously controlled trial to date. Current research is expanding into post-surgical lung cancer immunomodulation12, chemoradiotherapy combination strategies in NSCLC20, and the novel application of managing immune-related adverse events from checkpoint inhibitor therapy16.

§07References